AngioDynamics Inc. Reports Strong Q3 Earnings and Upgrades Full‑Year Guidance
AngioDynamics Inc. (NASDAQ: ANGO), a U.S.‑based medical‑device manufacturer that designs and markets interventional tools for peripheral vascular and non‑coronary diseases, announced its fiscal 2026 third‑quarter results on April 2, 2026. The company highlighted continued growth in its Med Tech segment, the first time in six consecutive quarters that the division reported double‑digit sales expansion. In response, AngioDynamics revised its full‑year outlook upward, citing robust performance from its mechanical thrombectomy portfolio and the NanoKnife platform.
Quarterly Financial Highlights
| Metric | 2026 Q3 (Feb 28) | 2025 Q3 (Feb 28) | YoY % Change |
|---|---|---|---|
| Net sales | $78.4 million | $71.6 million | +8.9 % |
| Med Tech sales | $37.3 million | $30.6 million | +19 % |
| Med Device sales | $41.1 million | $40.8 million | +1.1 % |
| GAAP gross margin | 52.9 % | – | – |
| GAAP net loss | $0.19 per share | – | – |
| Adjusted net loss | $0.07 per share | $0.19 per share | $0.12 improvement |
| Adjusted EBITDA | $1.8 million | – | – |
The company’s adjusted earnings per share of –$0.07 beat analyst expectations by $0.04, and its revenue of $78.42 million exceeded forecasts by $1.65 million. These figures were reported by multiple outlets, including investing.com and seekingalpha.com, which both noted the beat in non‑GAAP EPS and revenue.
Drivers of Growth
- Mechanical Thrombectomy: The AlphaVac and AngioVac systems drove a 19 % increase in Med Tech sales. These devices are used for removing clots in large vessels, a procedure that has gained traction amid rising cardiovascular disease prevalence.
- NanoKnife Platform: CPT code updates accelerated adoption of the NanoKnife in prostate‑related procedures, contributing significantly to the Med Tech segment’s performance.
- Stability in Med Device: The Med Device division recorded a modest 1.1 % year‑over‑year rise, underscoring the company’s diversified portfolio.
Liquidity Position
AngioDynamics closed the quarter with $37.8 million in cash, cash equivalents, and marketable securities, providing a solid buffer to support ongoing research and development and potential capital expenditures.
Full‑Year Outlook Revision
Buoyed by the sixth consecutive quarter of double‑digit growth in its Med Tech business, AngioDynamics has increased its revenue and earnings guidance for the remainder of fiscal 2026. While the precise figures are not disclosed in the press release, analysts anticipate that the upward revision will reflect continued momentum in high‑growth segments and an improving margin profile.
Market Context
- Stock Performance: As of March 31, 2026, AngioDynamics traded at $11.94, down from a 52‑week high of $13.99. The company’s market capitalization stands at approximately $448.9 million.
- Historical Perspective: A 10‑year retrospective analysis from finanzen.net indicates that an investment of $100 in AngioDynamics ten years ago would have yielded only 7.86 shares, valued at $89.39 on March 31, 2026, reflecting a 10.61 % decline from the 10‑year ago price of $12.72.
Conclusion
AngioDynamics’ latest quarterly results underscore its ability to generate growth from both established and emerging medical‑technology platforms. The company’s proactive guidance upgrade signals confidence in its product pipeline and market trajectory. Investors should monitor the firm’s ability to sustain double‑digit expansion in Med Tech while managing margins and liquidity in a competitive healthcare equipment landscape.
